



(51) International Patent Classification:

C07D 403/12 (2006.01) *A61K 31/4155* (2006.01)
C07D 407/12 (2006.01) *A61P 29/00* (2006.01)
C07D 409/12 (2006.01)

(21) International Application Number:

PCT/EP2012/050830

(22) International Filing Date:

20 January 2012 (20.01.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11151876.7 24 January 2011 (24.01.2011) EP

(71) Applicant (for all designated States except US):
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Corporate Patents, Binger Str. 173, 55216 Ingelheim am Rhein (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANDERSKEWITZ, Ralf** [DE/DE]; Corporate Patents, Binger Str. 173, 55216 Ingelheim am Rhein (DE). **MARTYRES, Domnic** [GB/DE]; Corporate Patents, Binger Str. 173, 55216 Ingelheim am Rhein (DE). **OOST, Thorsten** [DE/DE]; Corporate Patents, Binger Str. 173, 55216 Ingelheim am Rhein (DE). **RIST, Wolfgang** [DE/DE]; Corporate Patents, Binger Str. 173, 55216 Ingelheim am Rhein (DE). **SEITHER, Peter** [DE/DE]; Corporate Patents, Binger Str. 173, 55216 Ingelheim am Rhein (DE).

(74) Agents: **WEYMANN, Markus** et al.; Boehringer Ingelheim Pharma GmbH & Co. KG, Corporate Patents, Binger Str. 173, 55216 Ingelheim am Rhein (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS



(57) Abstract: The present invention relates to pyrazole compounds of formula (1a) or (1b) and pharmaceutically acceptable salts thereof, wherein Ra, Rb, Rc, Rd, Y1, y2, y3, y4, y5, Z, R1, R2, n and R3 have one of the meanings as indicated in the specification and claims, to their use as medicaments, to pharmaceutical formulation containing said compounds and to pharmaceutical formulations said compounds in combination with one or more active substances. The compounds have CRTH2 antagonistic activity.